Why DataMEDS' Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This Point The recent surge in DataMEDS' (MEDS) stock following its acquisition of Helomics and a lab services business has left many investors wondering if this is a genuine bull run or just another flash in the pan phenomenon.
The 87% jump on September 15 and subsequent 275% increase have led some to believe that MEDS is the next big thing in medicine, but a closer look at the numbers reveals a more nuanced picture.
DataMEDS' acquisition of Helomics seems like a shrewd move, leveraging its existing resources to expand into new areas. However, when we examine Helomics' revenue, it's clear that something doesn't add up.